Resalis Therapeutics

Resalis Therapeutics is a biotechnology startup that is determined to address metabolic disorders through non-coding RNAs. The company's focus lies in targeting a master regulator of key pathways underlying obesity and fatty liver disease. Their lead program, RES-010, aims to provide a safe and convenient treatment offering substantial therapeutic impact, including durable weight loss and reduction of hepatic steatosis, with a unique understanding of the non-coding RNA drug modality and lipid metabolism. Founded in 2021 and headquartered in Italy, Resalis Therapeutics has received a significant €10.00M Series A investment on 04 January 2024 from notable investors Sunstone Capital and Claris Ventures. With robust preclinical evidence, the company is well-positioned to advance RES-010 into clinical trials for a range of metabolic disorders. This innovative approach to tackling metabolic diseases and the strategic investment support indicates the potential for Resalis Therapeutics to make a meaningful impact in the biotechnology and pharmaceutical industries.